Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C

Treatment of acute hepatitis C with pegylated IFN-α is highly beneficial, but its effectiveness is affected by a poor rate of acceptance and/or adherence to currently available regimens, especially in IVDU and women.